Lupin has collaborated with Alkem subsidiary Enzene Biosciences to launch the first ever cetuximab biosimilar in India. 

Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.

Lupin has pushed the US launch for a generic to Boehringer’s blockbuster COPD drug Spiriva to September as FDA action is now expected “latest by August”. Meanwhile, an acquisition of Medisol in France and ANDA submissions in the US are part of an ongoing focus on injectables.

Vanda is fighting FDA’s rejection of jet lag indication for Hetlioz as it faces generic competition for sleep-wake disorder treatment. Federal Circuit finds four Hetlioz patents invalid.